Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, will participate in the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. During the event, CEO Jonathan E. Lim will present an overview of the company and its pipeline. Additionally, Dr. Lim and CFO David M. Chacko will engage in one-on-one investor meetings. A live audio webcast of the presentation will be accessible online, with an archived replay available for 30 days afterward.

News Market Reaction – ERAS

-3.42%

-3.42% Session move

In the trading session that priced this news, ERAS declined 3.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 40^th annual J.P. Morgan Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company and pipeline at 3:45 pm Eastern Time on Monday, January 10, 2022. Dr. Lim and David M. Chacko, M.D., chief financial officer, will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

FAQ

What is Erasca's participation in the January 2022 J.P. Morgan Healthcare Conference?

Erasca will present at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET.

Who will represent Erasca at the J.P. Morgan Healthcare Conference?

CEO Jonathan E. Lim and CFO David M. Chacko will represent Erasca at the conference.

Where can I watch the Erasca presentation from the J.P. Morgan Healthcare Conference?

The presentation will be available via live audio webcast at Erasca.com/events.

Will there be a replay of Erasca's presentation at the conference?

Yes, an archived replay of the presentation will be available for 30 days after the event.

What is the focus of Erasca, Inc.?

Erasca is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.